Tuesday, October 28, 2014

News: Wright Medical Group, Inc. and Tornier N.V. Agree to Merge Creating Premier High-Growth Extremities-Biologics Company


Under the terms of the agreement, which has been unanimously approved by the boards of directors of both Wright and Tornier, each outstanding share of Wright common stock will be exchanged for 1.0309 ordinary shares of Tornier. Upon completion of the merger, Wright shareholders will own approximately 52% of the shares of the combined company on a fully diluted basis and Tornier shareholders will own approximately 48%. For Tornier shareholders, the exchange ratio implies a per share value for Tornier that represents a 28% premium to Tornier’s closing share price on October 24, 2014, the last trading day prior to the parties entering into the agreement.

Following the closing of the transaction, the combined company will conduct business as Wright Medical Group N.V. and will leverage the global strengths of both product brands as a pure play Extremities-Biologics business. The combined company will have its U.S. headquarters in Memphis, TN, where Wright’s current headquarters is located. Wright Medical Group N.V. will be led by Robert Palmisano, who will become president and chief executive officer of the combined company. David Mowry, Tornier’s president and chief executive officer, will become executive vice president and chief operating officer of the combined company. Wright Medical Group N.V.’s board of directors will be comprised of five representatives from Wright’s existing board and five representatives from Tornier’s existing board, including Robert Palmisano and David Mowry.

The merger of Wright and Tornier will create a mid-sized growth company uniquely positioned with leading technologies and specialized sales forces in three of the fastest growing areas of orthopaedics – Upper Extremities, Lower Extremities and Biologics. That leadership will be further enhanced by anticipated final U.S. Food and Drug Administration (FDA) premarket approval of Augment® Bone Graft, adding additional depth to what will be one of the most comprehensive extremity product portfolios in the industry as well as providing a platform technology for future new product development. The highly complementary nature of the two businesses will give the combined company significant diversity and scale across a range of geographies and product categories.

As announced separately today, Wright received an Approvable Letter from the FDA for its Premarket Approval Application (PMA) for Augment® Bone Graft. The approvable letter indicates that FDA determined Augment® Bone Graft to be safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications and is approvable subject to customary preapproval facilities inspections.
Robert Palmisano, president and chief executive officer of Wright, stated, “This combination will create the premier Extremities-Biologics company with a broad global reach. Together, we will have one of the most comprehensive upper and lower extremity product portfolios in the market, extending our leadership position and further accelerating our growth opportunities and path to profitability, all of which we believe will generate long-term value for our shareholders. In addition, this will provide our employees with opportunities for career growth and development as part of a much larger, dynamic organization.”

David Mowry, president and chief executive officer of Tornier, added, “Wright shares Tornier’s commitment to serving extremities specialists and building the leading global business in this market. Both companies have built a deep and loyal customer base and have highly complementary product portfolios, positioning the combined entity to deliver meaningful value to our shareholders. We believe that partnered together, Wright andTornier will become the fastest-growing company in the Extremities-Biologics industry.”
Palmisano continued, “Today’s positive news on the approvability of Augment Bone Graft is a major milestone that paves the way for commercialization in the U.S. and further underscores our strength in Biologics. This is expected to be a significant catalyst and meaningful new future growth driver for our business.”

Both companies will benefit from opportunities to accelerate growth through combined direct sales and distribution networks, a broad product portfolio and deep customer relationships. The joint products, R&D, sales and distribution talent, medical education and relationships will allow an increased focus on the needs of surgeon specialists. Similarly, patients will benefit from dedicated research and development teams that will power enhanced innovation across the combined product portfolio.

Financial Highlights

This stock-for-stock merger allows shareholders of the combined company to benefit from operational and cost synergies. Once integrated, the companies anticipate revenues of the combined business growing in the mid-teens and adjusted EBITDA margins approaching 20% in three to four years.

The amount of cost synergies is expected to be in the range of $40 million to $45 million anticipated to be fully realized by the third year after completion of the transaction. Expense synergy opportunities include: public company expenses, overlapping support function and systems costs, as well as process and vendor consolidation opportunities across the business.

Wright anticipates that the transaction will be accretive to the combined companies’ adjusted EBITDA in the second full-year after completion of the transaction.

Structure

Upon completion of the transaction, the businesses of Wright and Tornier will be combined and incorporated in the Netherlands, where Tornier has been incorporated and headquartered for approximately 8 years. Both companies agreed that maintaining Tornier’s domicile best supported the growth strategy driving the merger. Over the long term, it is anticipated that this structure will provide the company with more accessible cash flow, enhancing its ability to innovate and grow, creating long-term shareholder value.
The U.S. headquarters for the Lower Extremity and Biologics business will be based in Wright’s existing facility in Memphis, TN, and its Augment team will continue to be based at its facility in Franklin, TN. The U.S. headquarters for the Upper Extremity business will be based within Tornier’s existing facility in Bloomington, MN and its U.S. engineering center in Warsaw, IN.

The transaction is expected to be taxable, for U.S. federal income tax purposes, to shareholders of Wright.

The transaction is subject to the customary closing conditions, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as Wright and Tornier shareholder approval.

In addition, TMG Holdings Cooperatief U.A., an affiliate of Warburg Pincus, which holds approximately 22% of Tornier’s outstanding ordinary shares, has evidenced its support by entering into an agreement to vote in favor of the transaction.

The transaction is expected to close in the first half of 2015.

An investor presentation will be available on Wright’s investor website at www.wmt.com. More information about the transaction can also be found at www.ExtremitiesLeader.com.

Saturday, October 25, 2014

News: Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices



    • MEDIA

      1. NoImage
        PHOTO:

        CAPSTONE PTC™

        Image Courtesy of Medtronic, Inc.
      2. NoImage
        PHOTO:

        CLYDESDALE PTC™

        Image Courtesy of Medtronic, Inc.
      3. NoImage
        PHOTO:

        ANATOMIC PEEK PTC Cervical Fusion System

        Image Courtesy of Medtronic, Inc.
      4. NoImage
        PHOTO:

        CORNERSTONE-SR® Ti- Coated Anatomical Cervical Cage

        Image Courtesy of Medtronic, Inc.
    • Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices

    • MEMPHIS, TENN., - October 20, 2014 - Medtronic, Inc. (NYSE: MDT) introduced its Pure Titanium Coating (PTC) platform of interbody fusion devices for the spine today at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting in Boston. The PTC platform includes four products: the CAPSTONE PTC™ Spinal System, CLYDESDALE PTC™ Spinal System, ANATOMIC PEEK PTC Cervical Fusion System and CORNERSTONE-SR® Ti- Coated Anatomical Cervical Cage. 

      These devices are used to treat patients experiencing pain caused by compression of the spinal cord or nerve roots by helping to restore normal disc height. Disc height restoration may reduce the pressure on the nerve roots and the spinal cord and help alleviate much of the patient’s pain.

      Medtronic’s PTC devices represent an evolution in interbody fusion technology because they are constructed of a combination of the two materials most commonly used in interbody fusion procedures: titanium and polyetheretherketone (PEEK).  Both materials have a long clinical history of being used in orthopaedic and other medical implants. Surgeons have historically preferred interbody spacers made of titanium because of their strength and long clinical history. However, over the last 10 years PEEK has largely replaced titanium as the material of choice because it has a modulus of elasticity that is similar to human cortical bone1 and it does not show up on X-rays2. This radiolucency enables the surgeon to more easily assess the surgical site over time after surgery.  

      With the application of a thin layer of textured pure titanium about 1/10th of a millimeter thick to the top and bottom of each PEEK implant, the PTC devices possess attributes of both PEEK and titanium. Specifically, as demonstrated in mechanical testing compared to PEEK alone, the pure titanium coating has a greater coefficient of friction.3Additionally, this textured coating increases the surface area of the implant, which means there is more area for bone to come into contact with the surface of the implant.4 Yet, the titanium layer is thin enough that it does not change the radiolucency or mechanical properties of the underlying PEEK implant.  

      “Our PTC platform of interbody spacers is the result of our relentless effort to add value to our products and respond to surgeon needs by offering the advantages of combined materials in a single implant,” said Doug King, president of the Spine business and senior vice president at Medtronic. “We will continue to leverage our innovation to produce more advanced and differentiated products for surgeons to use to treat their patients.”
    • For Global Launch
      • The CAPSTONE PTC™ Spinal System and the CLYDESDALE PTC™ Spinal System received U.S. Food and Drug Administration (FDA) 510(k) clearance in March and launched in the U.S. in August. CE Mark (Conformité Européenne) was also received for both systems in July.
      • The CAPSTONE PTC™ Spinal System launched in Western Europe in September.
      • The CAPSTONE PTC™ Spinal System is expected to launch in Japan in November 2015 and CLYDESDALE PTC™ Spinal System is expected to launch in Japan in January 2016.

      For U.S. Launch Only
      • The ANATOMIC PEEK PTC Cervical Fusion System has received FDA 510(k) clearance and launched in the U.S. in September.

      For Launch Outside the U.S. Only
      • CORNERSTONE-SR® Ti- Coated Anatomical Cervical Cagehas received a CE Mark (Conformité Européenne) and launched in Western Europe in July.  This system is not for use in the United States or its territories.

      Indications for these devices are as follows:
      • CAPSTONE PTC™ Spinal System and CLYDESDALE PTC™ Spinal System are indicated for interbody fusion with autogenous bone graft in patients with Degenerative Disc Disease (DDD) at one or two levels from L2 to S1, for interbody fusions in the lower back or lumbar spine. These devices are intended to be used with supplemental fixation.

      • CORNERSTONE-SR® Ti- Coated Cervical Fusion System is indicated for:
      • degenerative discopathy and instability

      • primary surgery for certain progressive degenerative discopathies or extensive anterior decompression

      • revision surgery for failed disc operation, stenosis, and/or post-operative instability

      • pseudarthrosis or failed arthrodesis


      • The ANATOMIC PEEK PTC Cervical Fusion System is indicated for cervical interbody fusion procedures in skeletally mature patients with cervical disc disease at one level from the C2-C3 disc to the C7-T1 disc. The ANATOMIC PEEK PTC device is to be used with supplemental fixation and autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft.

      The CAPSTONE PTC™ Spinal System, the CLYDESDALE PTC™ Spinal System, CORNERSTONE-SR® Ti-Coated Cervical Fusion System, and the ANATOMIC PEEK PTC Cervical Fusion System incorporate the technology of Gary K. Michelson, M.D.

Monday, September 1, 2014

Education - Keeping fit aids bone and joint health whilst aging

Being physically active may significantly improve musculoskeletal and overall health, and minimize or delay the effects of aging, according to a review of the latest research on senior athletes (ages 65 and up) appearing in the September issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).
It long has been assumed that aging causes an inevitable deterioration of the body and its ability to function, as well as increased rates of related injuries such as sprains, strains and fractures; diseases, such as obesity and diabetes; and osteoarthritis and other bone and joint conditions. However, recent research on senior, elite athletes suggests usage of comprehensive fitness and nutrition routines helps minimize bone and joint health decline and maintain overall physical health.
"An increasing amount of evidence demonstrates that we can modulate age-related decline in the musculoskeletal system," said lead study author and orthopaedic surgeon Bryan G. Vopat, MD. "A lot of the deterioration we see with aging can be attributed to a more sedentary lifestyle instead of aging itself."
The positive effects of physical activity on maintaining bone density, muscle mass, ligament and tendon function, and cartilage volume are keys to optimal physical function and health. In addition, the literature recommends a combined physical activity regimen for all adults encompassing resistance, endurance, flexibility and balance training, "as safely allowable for a given person." Among the recommendations:
Resistance training - Prolonged, intense resistance training can increase muscle strength, lean muscle and bone mass more consistently than aerobic exercise alone. Moderately intense resistance regimens also decrease fat mass. Sustained lower and upper body resistance training bolsters bone density and reduces the risk of strains, sprains and acute fractures.
Endurance training - Sustained and at least moderately intensive aerobic training promotes heart health, increases oxygen consumption, and has been linked to other musculoskeletal benefits, including less accumulation of fat mass, maintenance of muscle strength and cartilage volumes. A minimum of 150 to 300 minutes a week of endurance training, in 10 to 30 minute episodes, for elite senior athletes is recommended. Less vigorous and/or short-duration aerobic regimens may provide limited benefit.
Flexibility and balance - Flexibility exercises are strongly recommended for active older adults to maintain range of motion, optimize performance and limit injury. Two days a week or more of flexibility training - sustained stretches and static/non-ballistic (non-resistant) movements - are recommended for senior athletes. Progressively difficult postures (depending on tolerance and ability) are recommended for improving and maintaining balance.
The study also recommends "proper" nutrition for older, active adults to optimize performance. For senior athletes, a daily protein intake of 1.0 to 1.5 g/kg is recommended, as well as carbohydrate consumption of 6 to 8 g/kg (more than 8 g/kg in the days leading up to an endurance event).
"Regimens must be individualized for older adults according to their baseline level of conditioning and disability, and be instituted gradually and safely, particularly for elderly and poorly conditioned adults," said Dr. Vopat. According to study authors, to improve fitness levels and minimize bone and joint health decline, when safely allowable, patients should be encouraged to continually exceed the minimum exercise recommendations.

Thursday, July 31, 2014

News - Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market

The global medical technology business, today announced its entry into the forefoot market with the launch of the HAT-TRICK™ Lesser Toe Repair System. Comprised of three separate repair options, the HAT-TRICK System includes products for metatarsophalangeal (MTP) ligament repair and reconstruction, a metatarsal osteotomy guide, and a revisable, all-PEEK implant for proximal Inter-phalanges (PIP) fusion, also known as hammer toe correction.

With the new HAT-TRICK System, surgeons have access to:
  • The HAT-TRICK MTP Joint Repair System, which provides a complete repair of the lesser MTP joint that is less invasive and more anatomic than current standard of care techniques,i
  • The HAT-TRICK Osteotomy Guide, which allows for a controlled, precise and reproducible approach that maintains the biomechanical axis of the metatarsal,ii and
  • The HAT-TRICK PIP Fusion System, which is an all-inside fusion of the PIP joint that is less invasive than other standard of care options.iii
"We are excited to expand our successful foot and ankle portfolio into the forefoot," says Mark Waugh, Vice President, Extremities and Limb Restoration for Smith & Nephew. "In addition to being a high-growth area, we believe there are tremendous opportunities for us to enhance the surgeon experience, simplify the procedures and, most importantly, improve patient outcomes."
Current market analysis shows that procedures such as lesser toe correction surgery are experiencing double-digit growth in the US.ivHowever, patient satisfaction research suggests that as many as 46% of hammer toe patients are unsatisfied with the outcome of their surgery using existing methods and technologies.v
"Although treating lesser toe deformities is extremely common, getting consistently predictable outcomes has eluded surgeons worldwide," explains orthopaedic surgeon Charles Saltzman, MD, chairman of the system's scientific advisory board. "Current standards of treatment are known to have unacceptably high complication rates."
The HAT-TRICK system is a new three-part approach designed to not only treat the deformity, but also the underlying problem that led to the deformity in the first place."

Sunday, March 30, 2014

News - Smith & Nephew launches cruciate retaining natural-motion knee implant

JOURNEYII Active knee solutions
Smith & Nephew released its JOURNEY II Cruciate Retaining knee replacement implant at the American Academy of Orthopaedic Surgeons Annual Meeting 2014.

According to a company press release, the PCL-sparing total knee replacement implant is designed to provide normal kinematics and increased patient satisfaction. The implant reproduces the shapes of the joint's hard surfaces and the normal force behavior of the soft tissues. This helps the soft tissue's readjustment after surgery and aids in returning the patient's stride to its natural motion.
“The JOURNEY II CR knee will be a key component of our total knee replacement portfolio,” Gaurav Agarwal, Smith & Nephew’s president of orthopaedic reconstruction, stated in the release. “The unique patient benefits of the JOURNEY II BCS knee have made it among the most popular implants we have ever introduced, and since our customers choose a PCL-sparing device in approximately one-half of knee replacement cases, we expect the new JOURNEY II CR to further drive adoption of the JOURNEY II system.”
Published at Haelio

Tuesday, March 25, 2014

News - Acumed launches Pelvic Plating System

Acumed Pelvic Plating System.  (PRNewsFoto/Acumed)
HILLSBORO, Ore.March 24, 2014 /PRNewswire-iReach/ -- Long known for its orthopaedic implants for trauma to the extremities, Acumed is venturing into a new and expanding market it feels has not seen adequate innovation in recent years:  orthopaedic implants and instrumentation for the surgical repair of fractures and joint disruptions of the pelvis.
Acumed's new Pelvic Plating System includes plates, screws and instrumentation designed to provide fixation for fractures, fusions, and osteotomies of the acetabulum, sacrum, ilium, and pelvic ring as well as treatment of sacroiliac joint dislocations and symphysis pubis disruptions.
More specifically, the System features both strategically pre-contoured and un-contoured plates, pre-contoured in places where it may save time and add secure fixation, and un-contoured in places to allow for buttressing of fractures or varying patient anatomy.  In addition, Acumed's new system allows for the option to bend any of the pelvic plates, utilizing instrumentation provided within the system.
Further, enhancements to traditional pelvic instrumentation (which include various pliers, cutters, clamps and drills) are incorporated with the intention to ease surgical techniques and reduce time in surgery to benefit both surgeon and patient.
Acumed's pelvic fracture system was developed in conjunction with leading trauma surgeons and is Acumed's first step in its plans to expand its presence in trauma.
"Acumed is focused on expanding our trauma presence in areas where we feel we can leverage engineering excellence and innovation to provide new solutions." says Rich Rice, Acumed Vice President of Extremities, Trauma and Biologics.
"We identified pelvic fractures as an indication where very little innovation has occurred in the last ten years," he adds. "Moreover, with the aging population in developed countries, we feel the incidence rate of pelvic fractures per year will increase and there will be a need for better solutions than are on the market today."

Wednesday, March 19, 2014

News - DEPUY SYNTHES ADDS FEATURES TO ATTUNE KNEE AT AAOS



DePuy Synthes Companies announced two new improvements to the company’s Attune Knee System on March 12, 2014 at the annual American Academy of Orthopaedic Surgeons meeting in New Orleans, Louisiana.

After introducing the Attune system a year ago and implanting more than 31,000 of the devices during that time, the company added a rotating platform knee and anatomic patella. Both additions have received PMA Supplemental Approval from the FDA.
According to the company, the rotating platform design increases the level of conformity to provide stability while delivering freedom of mobility. In addition, the rotating platform design gives the tibial insert the freedom to self-align and track with the femoral component throughout the range of motion, allowing surgeons the ability to position the rotating platform tibial base on the proximal tibia for maximum bony coverage.
The knee, says the company, builds on the LCS Complete Knee System and the SIGMA Rotating Platform Knee System. More than one million rotating platform knees have been provided for surgeons and patients around the world.
The anatomic patella works with the Attune knee femoral components, is unique to the company and is compatible with both the Attune fixed bearing and rotating platform knees. The patella, according to the company, is designed to have more natural sagittal plane kinematics than traditional dome style patella components. The more natural kinematics can reduce soft tissue interaction with the femoral component and thereby help prevent soft tissue irritation. Also, the unique kinematics of the anatomic patella can increase quadriceps efficiency in deep flexion, allowing the knee to more easily flex and extend.
For instance, studies show that between 10-20% of knee replacement patients are not completely satisfied with their knee replacement. A major contributing factor to this is anterior knee pain in the area of the patella. The anatomic patella was created to help address this need, and is designed to wrap around the knee in a more natural way and improve patella tracking.
Company officials told us that an early performance registry is showing “excellent” results. Multicenter studies are also being performed, but have not yet been completed. Early results, said the officials, are showing an improved range of motion and excellent stability.
Hannah McEwen, Ph.D., the company’s joint reconstruction director for knee product development, said the company was looking to address an unmet patient need. “The introduction of the knee and patella bring new options for patient care.”
Published at - Orthopedics This Week

Thursday, March 13, 2014

Education - Comparable Outcomes for Outpatient, Inpatient Orthopaedic Surgeries



As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery. However, readmission rates, although statistically "non-significant," were higher for outpatient procedures. In a related study, a very low complication rate (.23 percent) was found in a review of more than 28,737 hand and upper extremity surgeries at an outpatient specialty clinic.
Many surgeons are now performing TJR as a same day procedure, with patients discharged within 24 hours of surgery. Outpatient TJR has "the potential benefit to cut costs and improve patient satisfaction," however, concerns for patient recovery, as well as increased Medicare scrutiny and financial penalties for unplanned hospital readmissions within 30 days of surgery, is deterring some doctors and hospitals from routinely performing outpatient surgeries, said David N. Vegari, MD, a Philadelphia orthopaedic surgeon and lead author of the study, "Implications of Outpatient vs. Inpatient Total Joint Arthroplasty on Hospital Readmission Rates."
In the study, researchers reviewed outcomes for 243 patients who underwent either outpatient (137 patients) or inpatient (106 patients) total knee or total hip replacement surgery between September 2010 and May 2011. Patients receiving outpatient surgery had a body mass index (BMI) less than or equal to 40 kg/m2, as well as no cardiopulmonary issues, sleep apnea, history of deep venous thrombosis or pulmonary embolus (blood clots).  To qualify for outpatient surgery, patients also had to live less than one hour from the hospital and have "good" family support. The inpatient group had comparable pre-surgical qualifications, but per surgeon preference, stayed in the hospital for two days.
Following the surgery, each patient completed a telephone survey consisting of 14 questions related to hospital readmissions, unplanned care and patient satisfaction.
Among the outcomes:
  • Of the 137 outpatient procedures (THA and TKA), 14 patients (10.2 percent) were readmitted within a 30-day period following surgery while seven of 106 inpatient THA and TKA (6.6 percent) procedures (6.6 percent) required hospital readmission within 30 days.  This difference was not statistically significant.
  • When including emergency department (ED) visits and urgent care visits as unplanned care episodes to the readmission number, 17 (12.4 percent) of outpatients required either hospital readmission or an unplanned care episode compared to seven (6.7 percent) inpatient TJRs.
  • Only one (2.2 percent) of the outpatient THA patients was readmitted within 30 days of surgery and no inpatient THAs required readmission.
  • The length of hospital stay had no effect on patient satisfaction measurements.
Outpatient TJR has "the potential benefit to cut costs and improve patient satisfaction," said Dr. Vegari. "With the trend toward higher readmissions in outpatient surgery, larger studies are needed to better understand the causes. By doing so, we can potentially help lower these rates to improve safety and efficacy of outpatient surgery."
In the related study, "The Safety of Outpatient Hand and Upper Extremity Surgery – A Statistical Review of Complications in 28,737 Cases," presented on Wednesday, March 12, adverse events were defined as those causing harm to a patient or leading to additional treatment. Using state reportable adverse events criteria as a guideline, the cases were divided into seven categories: infection, post-operative transfer to a hospital, wrong site surgery, retention of a foreign object, post-operative deep vein thrombosis, medication error and other "surgery-related complications."  The adverse events were then analyzed to see if they led to additional laboratory testing, hospital admission, return to the operating room, emergency department visits, and/or physical or mental disability.
Among the findings:
  • There were 65 reportable events for an overall complication rate of .23 percent. There were no mortalities.
  • There were 21 infections (.7 percent), of which 10 were treated with antibiotics and one returned to the operating suite for incision and drainage. Seventeen patients (.06 percent) were transferred from the surgery center to the hospital post-operatively. The causes of the post-operative transfers included: irregular heart rhythms, uncontrolled hypertension, low-oxygen saturations, issues with pain control, drowsiness and generalized seizures.
  • Twenty-one patients (.7 percent) were admitted to the hospital during the post-operative period, most often for poor pain control.
  • There were no cases of wrong site surgery or retained foreign bodies.
  • There was one case of post-operative pulmonary embolism, and one medication error that led to a rash.
  • Four patients were returned to the operating room due to excessive bleeding or hematoma formation.
"With proper patient selection, extremely low complication rates can be achieved in hand and upper extremity surgery in outpatient surgery centers," said Sameer Jain, MD, a University of Pittsburgh orthopaedic surgeon specializing in sports medicine and hand and upper extremity surgery and lead study author of the study. "This is important, because as the cost of medicine rises and anesthesia continues to improve, more and more procedures are being completed on an outpatient basis.
"Our study supports the view that outpatient surgery can offer patients and physicians options for safe, cost-effective surgical care, offering improved patient comfort, increased efficiency and low complication rates," said Dr. Jain.
View disclosure statement:
Published at - PR News Wire